Stevanato Group S.p.A. (STVN) shares plummeted 5.16% in intraday trading on Tuesday, despite the company reporting better-than-expected second-quarter results. The sharp decline suggests that investors may be focusing on the company's outlook, which appears to have fallen short of market expectations.
The Italian-based medical technology company reported Q2 2025 revenue of €280.0 million, surpassing analysts' estimates of €268.3 million. Net income came in at €29.7 million, also beating the expected €29.2 million. The company's earnings per share (EPS) of €0.11 met consensus estimates.
However, Stevanato's forward guidance seems to have dampened investor enthusiasm. The company forecasts full-year revenue between €1,160 million and €1,190 million, with adjusted EBITDA ranging from €288.5 million to €301.8 million. The projected adjusted EPS for the fiscal year is set at €0.50 to €0.54. These figures, while showing growth, may not have met the market's more optimistic expectations, potentially explaining the stock's significant drop despite the earnings beat.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.